NCT02790073View on ClinicalTrials.gov

Phase 2 Study With SNF472 in Calciphylaxis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 15, 2017

Study Completion Date

November 15, 2017

Conditions
CalciphylaxisCalcific Uremic Arteriolopathy
Interventions
DRUG

SNF472

SNF472 for calciphylaxis

Trial Locations (3)

55404

Davita Clinical Research, Minneapolis

02451

Fresenius Medical Services, Waltham

Unknown

Salford Royal Hospital, Salford

All Listed Sponsors
lead

Sanifit Therapeutics S. A.

OTHER

NCT02790073 - Phase 2 Study With SNF472 in Calciphylaxis Patients | Biotech Hunter | Biotech Hunter